# Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) as a Biomarker of Neurodysfunction

**Authors:** Victoria Linden de Rezende, Khiany Mathias, Lucineia Gainski Danielski, Tatiana Barichello, Fabricia Petronilho

PMC · DOI: 10.1007/s12017-026-08912-1 · 2026-03-12

## TL;DR

This review explores how suPAR, a marker of chronic inflammation, may be linked to brain dysfunction and neuroinflammation.

## Contribution

The paper highlights suPAR's emerging role as a biomarker connecting systemic inflammation to central nervous system dysfunction.

## Key findings

- Higher suPAR levels are associated with memory impairment and poor outcomes after brain injury.
- suPAR reflects neuroinflammation and blood-brain barrier disruption in immune-activated conditions.
- Study designs and populations vary, limiting clear mechanistic understanding of suPAR's role in the CNS.

## Abstract

The inflammatory response is essential for host defense, but its persistence can lead to chronic systemic inflammation (CSI). Soluble urokinase-type plasminogen activator receptor (suPAR) has emerged as a reliable biomarker of CSI because elevated levels consistently indicate the presence and progression of chronic disease as well as increased mortality risk. There is growing evidence that CSI influences neurovascular regulation, including changes in blood-brain barrier (BBB) integrity, which suggests that suPAR may also be relevant to central nervous system (CNS) processes. This narrative review summarizes current findings on suPAR in CSI and examines its emerging implications for CNS. Higher suPAR concentrations have been linked to working memory impairment, executive dysfunction and worse clinical outcomes after brain injury. Evidence also indicates that suPAR reflects neuroinflammatory activity and BBB disruption, especially in conditions marked by heightened immune activation. However, available studies differ widely in design, sample type, follow-up duration and population characteristics, which limits mechanistic interpretation. Although suPAR appears to be a promising biomarker connecting systemic inflammation to CNS dysfunction, its role within the brain remains unclear. Future studies should determine its cellular origin, clarify its involvement in inflammatory signaling pathways and establish its predictive and prognostic value.

## Linked entities

- **Proteins:** Su(par) (Suppressor of paralog)
- **Diseases:** brain injury (MONDO:0043510)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, PLAU (plasminogen activator, urokinase) [NCBI Gene 5328] {aka ATF, BDPLT5, QPD, UPA, URK, u-PA}, JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726] {aka AP-1}, FPR2 (formyl peptide receptor 2) [NCBI Gene 2358] {aka ALX, ALXR, FMLP-R-II, FMLPX, FPR2A, FPRH1}, PLAUR (plasminogen activator, urokinase receptor) [NCBI Gene 5329] {aka CD87, U-PAR, UPAR, URKR}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, KNG1 (kininogen 1) [NCBI Gene 3827] {aka BDK, BK, HAE6, HK, HMWK, KNG}, VTN (vitronectin) [NCBI Gene 7448] {aka V75, VN, VNT}, SERPINF2 (serpin family F member 2) [NCBI Gene 5345] {aka A2AP, AAP, ALPHA-2-PI, API, PLI, alpha2AP}, PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}, SERPINB2 (serpin family B member 2) [NCBI Gene 5055] {aka HsT1201, PAI, PAI-2, PAI2, PLANH2}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, Plaur (plasminogen activator, urokinase receptor) [NCBI Gene 18793] {aka Cd87, u-PAR, uPAR}, C1QBP (complement C1q binding protein) [NCBI Gene 708] {aka COXPD33, GC1QBP, HABP1, SF2AP32, SF2p32, gC1Q-R}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}
- **Diseases:** atherosclerosis (MESH:D050197), diabetes (MESH:D003920), CNS Dysfunction (MESH:D002493), coronary artery disease (MESH:D003324), neurocognitive disorders (MESH:D019965), neurodegenerative (MESH:D019636), T1D (MESH:D003922), acute (MESH:D000208), pancreatic beta-cell dysfunction (MESH:D010195), cardiovascular and renal diseases (MESH:D002318), neuroinflammation (MESH:D000090862), cognitive decline (MESH:D003072), dysfunction (MESH:D006331), brain injuries (MESH:D001930), disease (MESH:D004194), glomerular kidney diseases (MESH:D007674), declines in executive function (MESH:D060825), infection (MESH:D007239), HIV (MESH:D015658), aneurysmal subarachnoid hemorrhage (MESH:D013345), ischemic stroke (MESH:D002544), memory deficits (MESH:D008569), BBB impairment (MESH:C536830), traumatic brain injury (MESH:D000070642), CSI (MESH:D007249), endothelial dysfunction (MESH:D014652), hypertension (MESH:D006973), HF (MESH:D006333), infectious (MESH:D003141), neurological disorders (MESH:D009461), sepsis (MESH:D018805), tumor (MESH:D009369), migraine (MESH:D008881), migraine with aura (MESH:D020325), -ischemic (MESH:D002545), AKI (MESH:D058186), dementia (MESH:D003704)
- **Chemicals:** polysaccharides (MESH:D011134), FITC (MESH:D016650), GPI (MESH:D017261), CSI (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676], Mus musculus (house mouse, species) [taxon 10090]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12982231/full.md

---
Source: https://tomesphere.com/paper/PMC12982231